Avalyn Pharma is led by CEO Lyn Baranowski, who previously worked at Pearl Therapeutics, where she helped develop treatments ...
Abstract: Idiopathic Pulmonary Fibrosis (IPF) and Tuberculosis (TB) are both complicated diseases and gradually increasing their incidence rates worldwide. Some population-based studies reported that ...
Stocktwits on MSN
TRVI stock’s five-day rally pushes it to an all-time high – here’s what’s happening
Underwriters were given a 30-day option to purchase up to 1.74 million additional shares. ・Trevi is currently developing Haduvio, its treatment for chronic cough in patients with idiopathic pulmonary ...
New Haven-based Trevi Therapeutics Inc. disclosed it is seeking to raise $150 million through a public stock offering to ...
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
Isolated antineutrophil cytoplasmic antibody-associated interstitial lung disease is an increasingly recognized fibrotic ILD phenotype.
A protein called PIEZO1, which is linked to mechanical stress, may play a key role in driving pulmonary fibrosis, a study ...
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies ...
Cautionary Language Concerning Forward-Looking Statements ...
Deupirfenidone slowed the progression of lung disease over 26 weeks in patients with idiopathic pulmonary fibrosis in a clinical trial.
Haisco Pharmaceutical Group Co. Ltd. has disclosed new lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of idiopathic pulmonary fibrosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results